

Japan Locally Advanced Pancreatic Cancer Market - 2024-2033

<https://marketpublishers.com/r/JF3C04DAD1EDEN.html>

Date: February 2026

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: JF3C04DAD1EDEN

Abstracts

The Japan Locally Advanced Pancreatic Cancer Market was valued at US\$ 47.09 million in 2024 and is anticipated to reach US\$ 89.04 million by 2033, at a CAGR of 0.074 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Locally Advanced Pancreatic Cancer Market.

This report delivers a comprehensive overview of the Japan Locally Advanced Pancreatic Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Locally Advanced Pancreatic Cancer Market. The Japan Locally Advanced Pancreatic Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Locally Advanced Pancreatic Cancer Market Scope:

Key Players

Bristol-Myers Squibb Company

Pfizer Inc.

Merck & Co., Inc.

Fresenius Kabi AG

Teva Pharmaceutical Industries Ltd

F. Hoffmann-La Roche Ltd.

Sun Pharmaceutical Industries Ltd.

Merus N.V.

CHEPLAPHARM Arzneimittel GmbH

Bayer AG

Eli Lilly and Company

MITSUBISHI HEAVY INDUSTRIES, LTD.

Major Highlights

This report delivers a comprehensive overview of the Japan Locally Advanced Pancreatic Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Locally Advanced Pancreatic Cancer Market. The Japan Locally Advanced Pancreatic Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Therapy
- 2.4. Snippet by End-User

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Adoption of Targeted and Immunotherapies
 - 3.1.1.2. Rising Incidence of Pancreatic Cancer in an Aging Population
 - 3.1.1.3. XX
 - 3.1.2. Restraints
 - 3.1.2.1. Delayed Diagnosis and Limited Early Detection Tools
 - 3.1.2.2. Severe Side Effects of Chemotherapy
 - 3.1.2.3. XX
 - 3.1.3. Opportunity
 - 3.1.3.1. Advancements in Precision Medicine
 - 3.1.3.2. XX
- 3.2. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established leaders with the largest-selling Brand
 - 4.1.3. Market leaders with established Product
- 4.2. CXO Perspectives
- 4.3. Latest Developments and Breakthroughs

- 4.4. Case Studies/Ongoing Research
- 4.5. Regulatory and Reimbursement Landscape
- 4.6. Porter's Five Forces Analysis
- 4.7. Supply Chain Analysis
- 4.8. Patent Analysis
- 4.9. SWOT Analysis
- 4.10. Unmet Needs and Gaps
- 4.11. Recommended Strategies for Market Entry and Expansion
- 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.13. Pricing Analysis and Price Dynamics
- 4.14. Key Opinion Leaders

5. JAPAN LOCALLY ADVANCED PANCREATIC CANCER MARKET, BY THERAPY

- 5.1. Introduction
 - 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
 - 5.1.2. Market Attractiveness Index, By Therapy
- 5.2. Chemotherapy*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. Folfirinox
 - 5.2.4. Gemcitabine
 - 5.2.5. Nab-Paclitaxel
 - 5.2.6. Cisplatin
 - 5.2.7. Others
- 5.3. Surgery
 - 5.3.1. Whipple Procedure
 - 5.3.2. Distal Pancreatectomy
 - 5.3.3. Total Pancreatectomy
- 5.4. Radiation Therapy
- 5.5. Targeted Therapy
 - 5.5.1. Larotrectinib
 - 5.5.2. Entrectinib
- 5.6. Immunotherapy

6. JAPAN LOCALLY ADVANCED PANCREATIC CANCER MARKET, BY END-USER

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

- 6.1.2. Market Attractiveness Index, By End-User
- 6.2. Hospitals*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Specialty Clinics
- 6.4. Research Institutions

7. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

- 7.1. Competitive Overview and Key Market Players
- 7.2. Market Share Analysis and Positioning Matrix
- 7.3. Strategic Partnerships, Mergers & Acquisitions
- 7.4. Key Developments in Product Portfolios and Innovations
- 7.5. Company Benchmarking

8. COMPANY PROFILES

- 8.1. Bristol-Myers Squibb Company
 - 8.1.1. Company Overview
 - 8.1.2. Product Portfolio
 - 8.1.2.1. Product Description
 - 8.1.2.2. Product Key Performance Indicators (KPIs)
 - 8.1.2.3. Historic and Forecasted Product Sales
 - 8.1.2.4. Product Sales Volume
 - 8.1.3. Financial Overview
 - 8.1.3.1. Company Revenue's
 - 8.1.3.2. Geographical Revenue Shares
 - 8.1.3.3. Revenue Forecasts
 - 8.1.4. Key Developments
 - 8.1.4.1. Mergers & Acquisitions
 - 8.1.4.2. Key Product Development Activities
 - 8.1.4.3. Regulatory Approvals, etc.
 - 8.1.5. SWOT Analysis
- 8.2. Pfizer Inc.
- 8.3. Merck & Co., Inc.
- 8.4. Fresenius Kabi AG
- 8.5. Teva Pharmaceutical Industries Ltd
- 8.6. F. Hoffmann-La Roche Ltd.*
- 8.7. Sun Pharmaceutical Industries Ltd.

8.8. Merus N.V.

8.9. CHEPLAPHARM Arzneimittel GmbH

8.10. Bayer AG

8.11. Eli Lilly and Company

8.12. MITSUBISHI HEAVY INDUSTRIES, LTD. (*LIST NOT EXHAUSTIVE)

9. ASSUMPTIONS AND RESEARCH METHODOLOGY

9.1. Data Collection Methods

9.2. Data Triangulation

9.3. Forecasting Techniques

9.4. Data Verification and Validation

10. APPENDIX

10.1. About Us and Services

10.2. Contact Us

I would like to order

Product name: Japan Locally Advanced Pancreatic Cancer Market - 2024-2033

Product link: <https://marketpublishers.com/r/JF3C04DAD1EDEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JF3C04DAD1EDEN.html>